Apellis Pharmaceuticals (APLS) PT Lowered to $45 at TD Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 38 | New: 6
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 38 | New: 6
Join SI Premium – FREE
TD Cowen analyst Phil Nadeau lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $45.00 (from $50.00) while maintaining a Buy rating.
You May Also Be Interested In
- Wesfarmers Ltd. (WES:AU) (WFAFF) PT Lowered to AUD73 at JPMorgan
- Laopu Gold (6181:HK) PT Lowered to HK$330 at Goldman Sachs
- Tsingtao Brewery Co Ltd (600600:CH) PT Lowered to RMB52 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
